Cancer Research Landon Prizes for Basic and Translational Cancer Research  Tumor Immunology: New Perspectives
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Supplementary Data
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Cinar, B.
Right arrow Articles by Freeman, M. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cinar, B.
Right arrow Articles by Freeman, M. R.
[Cancer Research 65, 2547-2553, April 1, 2005]
© 2005 American Association for Cancer Research


Priority Reports

Post-Transcriptional Regulation of the Androgen Receptor by Mammalian Target of Rapamycin

Bekir Cinar1, Arrigo De Benedetti2 and Michael R. Freeman1

Departments of 1 Urology and Surgery, Urological Diseases Research Center, Children's Hospital Boston, Harvard Medical School, Boston, Massachusetts and 2 Department of Biochemistry and Molecular Biology, Louisiana State University Health Sciences Center, Shreveport, Louisiana

Requests for reprints: Michael R. Freeman, Children's Hospital Boston, Harvard Medical School, Enders Room 1161, 300 Longwood Avenue, Boston, MA 02115. Phone: 617-355-6054; Fax: 617-730-0238; E-mail: michael.freeman{at}childrens.harvard.edu.

Heparin-binding epidermal growth factor-like growth factor (HB-EGF), an ErbB1 ligand and prostate stromal growth factor, is an antagonist of androgen receptor (AR) function. In the LNCaP prostate cancer model, HB-EGF reduced AR protein levels and AR transactivation without affecting AR mRNA level or protein turnover. The signal to attenuate AR was mediated by the mammalian target of rapamycin, as shown by genetic and pharmacologic methods, and was independent of ErbB2/HER-2, extracellular signal-regulated kinase 1/2, and p38 mitogen-activated protein kinase pathways. Additional evidence suggests that AR protein levels are highly sensitive to regulation by cap-dependent mRNA translation. These findings reveal a novel mechanism for regulation of AR by a classic growth factor system and indicate that a rapamycin-sensitive post-transcriptional pathway can attenuate or possibly bypass AR-mediated signaling.

Key Words: ErbB1/EGFR • phosphoinositide-3-kinase (PI3K) • Akt/protein kinase B (PKB) • rapamycin • S6 kinase (S6K1) • prostate cancer




This article has been cited by other articles:


Home page
Nucleic Acids ResHome page
P.-H. Chen, Y.-P. Tsao, C.-C. Wang, and S.-L. Chen
Nuclear receptor interaction protein, a coactivator of androgen receptors (AR), is regulated by AR and Sp1 to feed forward and activate its own gene expression through AR protein stability
Nucleic Acids Res., January 17, 2008; 36(1): 51 - 66.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
A. Schayowitz, G. Sabnis, V. C.O. Njar, and A. M.H. Brodie
Synergistic effect of a novel antiandrogen, VN/124-1, and signal transduction inhibitors in prostate cancer progression to hormone independence in vitro
Mol. Cancer Ther., January 1, 2008; 7(1): 121 - 132.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
B. Cinar, N. K. Mukhopadhyay, G. Meng, and M. R. Freeman
Phosphoinositide 3-Kinase-independent Non-genomic Signals Transit from the Androgen Receptor to Akt1 in Membrane Raft Microdomains
J. Biol. Chem., October 5, 2007; 282(40): 29584 - 29593.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
C. Wu and J. Huang
Phosphatidylinositol 3-Kinase-AKT-Mammalian Target of Rapamycin Pathway Is Essential for Neuroendocrine Differentiation of Prostate Cancer
J. Biol. Chem., February 9, 2007; 282(6): 3571 - 3583.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
I. V. Litvinov, D. J. Vander Griend, L. Antony, S. Dalrymple, A. M. De Marzo, C. G. Drake, and J. T. Isaacs
Androgen receptor as a licensing factor for DNA replication in androgen-sensitive prostate cancer cells
PNAS, October 10, 2006; 103(41): 15085 - 15090.
[Abstract] [Full Text] [PDF]


Home page
CarcinogenesisHome page
L.G. Wang, X.M. Liu, and J.W. Chiao
Repression of androgen receptor in prostate cancer cells by phenethyl isothiocyanate
Carcinogenesis, October 1, 2006; 27(10): 2124 - 2132.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
L. Xin, M. A. Teitell, D. A. Lawson, A. Kwon, I. K. Mellinghoff, and O. N. Witte
Progression of prostate cancer by synergy of AKT with genotropic and nongenotropic actions of the androgen receptor
PNAS, May 16, 2006; 103(20): 7789 - 7794.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2005 by the American Association for Cancer Research.